Plenary Talk: Interspike Interval Distribution of Neuronal Model with distributed delay: Emergence of unimodal, bimodal and Power law @ Sathyam Hall
Aug 13 @ 1:20 pm – 2:00 pm

karmeshuKarmeshu, Ph.D.
Dean & Professor, School of Computer & Systems Sciences & School of Computational & Integrative Sciences, Jawaharlal Nehru University, India.

Interspike Interval Distribution of Neuronal Model with distributed delay: Emergence of unimodal, bimodal and Power law

The study of interspike interval distribution of spiking neurons is a key issue in the field of computational neuroscience. A wide range of spiking patterns display unimodal, bimodal  ISI patterns including power law behavior. A challenging problem is to understand the biophysical mechanism which can generate  the empirically observed patterns. A neuronal model with distributed delay (NMDD) is proposed and is formulated as an integro-stochastic differential equation which corresponds to a non-markovian process. The widely studied IF and LIF models become special cases of this model. The NMDD brings out some interesting features when excitatory rates are close to inhibitory  rates rendering the drift close to zero. It is interesting that NMDD model with gamma type memory kernel can also account for bimodal ISI pattern. The mean delay of the memory kernels plays a significant role in bringing out the transition from unimodal to bimodal  ISI distribution. It is interesting to note that when a collection of neurons group together and fire together, the ISI distribution exhibits  power law.


Invited Talk: Targeting aberrant cancer kinome using rationally designed nano-polypharmaceutics @ Acharya Hall
Aug 13 @ 2:05 pm – 2:29 pm

ManzoorManzoor K, Ph.D.
Professor, Centre for Nanoscience & Molecular Medicine, Amrita University

Targeting aberrant cancer kinome using rationally designed nano-polypharmaceutics

Manzoor Koyakutty, Archana Ratnakumary, Parwathy Chandran, Anusha Ashokan, and Shanti Nair

`War on Cancer’ was declared nearly 40 years ago. Since then, we made significant progress on fundamental understanding of cancer and developed novel therapeutics to deal with the most complex disease human race ever faced with. However, even today, cancer remains to be the unconquered `emperor of all maladies’. It is well accepted that meaningful progress in the fight against cancer is possible only with in-depth understanding on the molecular mechanisms that drives its swift and dynamic progression. During the last decade, emerging new technologies such as nanomedicine could offer refreshing life to the `war on cancer’ by way of providing novel methods for molecular diagnosis and therapy.

In the present talk, we discuss our approaches to target critically aberrant cancer kinases using rationally designed polymer-protein and protein-protein core-shell nanomedicines. We have used both genomic and proteomic approaches to identify many intimately cross-linked and complex aberrant protein kinases behind the drug resistance and uncontrolled proliferation of refractory leukemic cells derived from patients. Small molecule inhibitors targeted against oncogenic pathways in these cells were found ineffective due to the involvement of alternative survival pathways. This demands simultaneous inhibition more than one oncogenic kinases using poly-pharmaceutics approach. For this, we have rationally designed core-shell nanomedicines that can deliver several small molecules together for targeting multiple cancer signalling. We have also used combination of small molecules and siRNA for combined gene silencing together with protein kinase inhibition in refractory cancer cells. Optimized nanomedicines were successfully tested in patient samples and found enhanced cytotoxicity and molecular specificity in drug resistant cases.

Nano-polypharmaceutics represents a new generation of nanomedicines that can tackle multiple cancer mechanisms simultaneously. Considering the complexity of the disease, such therapeutic approaches are not simply an advantage, but indispensable.

We thank Dept. of Biotechnology and Dept. Of Science and Technology,Govt. of India for the financial support through `Thematic unit of Excellence in Medical NanoBiotechnology’ and `Nanomedicine- RNAi programs’.